Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannah L Smith

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Cancers|April 9, 2020
Exploring the Synergy between PARP and CHK1 Inhibition in Matched <i>BRCA2</i> Mutant and Corrected CellsHannah L Smith, Lisa Prendergast, Nicola J Curtin
Journal of the American Veterinary Medical Association|September 19, 2024
Ultrasound biomicroscopy in dogs suggests postoperative ocular hypertension may be associated with ciliary cleft changes related to cataract surgeryHannah L Smith, Kim R Love, Hans D Westermeyer
British Journal of Cancer|July 4, 2024
ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitorsHannah L Smith, Elaine Willmore, Lisa Prendergast, et al.
Cells|August 9, 2024
Elevated Salt or Angiotensin II Levels Induce CD38+ Innate Immune Cells in the Presence of Granulocyte-Macrophage Colony Stimulating FactorHannah L Smith, Bethany L Goodlett, Shobana Navaneethabalakrishnan, et al.
Expert Reviews in Molecular Medicine|June 9, 2020
DNA damage checkpoint kinases in cancerHannah L Smith, Harriet Southgate, Deborah A Tweddle, et al.
Clinical Science (London, England : 1979)|June 23, 2025
Hypertension: a lymphatic disease?Sunitha Konatham, Bethany L Goodlett, Hannah L Smith, et al.
Cancers|November 26, 2022
Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and SchedulingHannah L Smith, Elaine Willmore, Asima Mukhopadhyay, et al.
International Journal of Molecular Sciences|February 25, 2023
Tri-Lineage Differentiation Potential of Osteosarcoma Cell Lines and Human Bone Marrow Stromal Cells from Different Anatomical LocationsHannah L Smith, Juliet C Gray, Stephen A Beers, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 26, 2024
Developing a 3D bone model of osteosarcoma to investigate cancer mechanisms and evaluate treatmentsHannah L Smith, Stephen A Beers, Janos M Kanczler, et al.
International Journal of Molecular Sciences|August 6, 2020
The Role of Pre-Clinical 3-Dimensional Models of OsteosarcomaHannah L Smith, Stephen A Beers, Juliet C Gray, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Cancers|April 9, 2020
Exploring the Synergy between PARP and CHK1 Inhibition in Matched <i>BRCA2</i> Mutant and Corrected CellsHannah L Smith, Lisa Prendergast, Nicola J Curtin
Journal of the American Veterinary Medical Association|September 19, 2024
Ultrasound biomicroscopy in dogs suggests postoperative ocular hypertension may be associated with ciliary cleft changes related to cataract surgeryHannah L Smith, Kim R Love, Hans D Westermeyer
British Journal of Cancer|July 4, 2024
ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitorsHannah L Smith, Elaine Willmore, Lisa Prendergast, et al.
Cells|August 9, 2024
Elevated Salt or Angiotensin II Levels Induce CD38+ Innate Immune Cells in the Presence of Granulocyte-Macrophage Colony Stimulating FactorHannah L Smith, Bethany L Goodlett, Shobana Navaneethabalakrishnan, et al.
Expert Reviews in Molecular Medicine|June 9, 2020
DNA damage checkpoint kinases in cancerHannah L Smith, Harriet Southgate, Deborah A Tweddle, et al.
Clinical Science (London, England : 1979)|June 23, 2025
Hypertension: a lymphatic disease?Sunitha Konatham, Bethany L Goodlett, Hannah L Smith, et al.
Cancers|November 26, 2022
Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and SchedulingHannah L Smith, Elaine Willmore, Asima Mukhopadhyay, et al.
International Journal of Molecular Sciences|February 25, 2023
Tri-Lineage Differentiation Potential of Osteosarcoma Cell Lines and Human Bone Marrow Stromal Cells from Different Anatomical LocationsHannah L Smith, Juliet C Gray, Stephen A Beers, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 26, 2024
Developing a 3D bone model of osteosarcoma to investigate cancer mechanisms and evaluate treatmentsHannah L Smith, Stephen A Beers, Janos M Kanczler, et al.
International Journal of Molecular Sciences|August 6, 2020
The Role of Pre-Clinical 3-Dimensional Models of OsteosarcomaHannah L Smith, Stephen A Beers, Juliet C Gray, et al.
Pageof 4